Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613228 | 0.80 | DAO (0.44) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL1045734 | 0.79 | CES2 (0.46) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL8220202 | 0.78 | PIK3CA (0.44) | HTTALDH1A1DAOMAOB | |
| SCHEMBL8220196 | 0.78 | SLC6A2 (0.44) | DAOMPO | |
| SCHEMBL8256923 | 0.78 | CA6 (0.50) | ALDH1A1 | |
| SCHEMBL20245287 | 0.78 | MAPT (0.41) | — | |
| SCHEMBL27057408 | 0.78 | DAO (0.44) | ALDH1A1DAO | |
| SCHEMBL3299911 | 0.78 | CYP17A1 (0.52) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL16105820 | 0.78 | DAO (0.55) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL7496943 | 0.77 | DAO (0.42) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | NEKTAR THERAPEUTICS (US) | 2022-02-08 | — | — | US | disclosed |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-14 | — | — | US | disclosed |
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS | 2019-09-05 | — | — | US | disclosed |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | NEKTAR THERAPEUTICS (US) | 2019-06-18 | — | — | US | disclosed |
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| WO-2013048949-A2 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2009045385-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | OPRK1, OPRM1, OPRD1 | HTT 3053/4885ALDH1A1 916/4885CYP17A1 3320/4885 |
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | HTT 1317/4885ALDH1A1 869/4885CYP17A1 2825/4885 |
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | OPRM1, OPRK1, OPRD1 | HTT 2490/4885ALDH1A1 828/4885CYP17A1 2886/4885 |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | TRPC5, TRPM5, TRPC4 | HTT 2837/4885ALDH1A1 1568/4885CYP17A1 4257/4885 |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | OPRK1, OPRM1, OPRD1 | HTT 3053/4885ALDH1A1 916/4885CYP17A1 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.